{{Rsnum
|rsid=1048977
|Gene=CDA
|Chromosome=1
|position=20618562
|Orientation=plus
|GMAF=0.3145
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CDA
}}{{PharmGKB
|RSID=rs1048977
|Name_s=CDA:435C>T, mRNA 614C>T, T145T
|Gene_s=CDA
|Feature=Exon/Syn
|Evidence=PubMed ID:15224082
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Variants identified in a screen of 13 genes involved in the gemcitabine drug metabolic pathway. For the synonymous CDA:435C>T (T145T) SNP, the T allele was at frequency 0.30 and 0.35 in Europeans and Africans, respectively. There was no significant difference between ethnic groups in genotype frequency distribution (p > 0.05). Study size: 178. Study population/ethnicity: Healthy, unrelated blood donors of European (n = 88) and African (n = 90) descent. Significance metric(s): Not significant, p > 0.05. Type of association: GN.
|Drugs=gemcitabine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110713
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1048977
|overall_frequency_n=3657
|overall_frequency_d=10758
|overall_frequency=0.339933
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}